AI summary · DOI: 10.64898/2026.11.13.26367865 · medRxiv: Neurology
PSEN1 loss-of-function variants do not cause early-onset Alzheimer's disease
The essentials
Across the cohorts examined, carriers of predicted PSEN1 null variants had no recorded early-onset dementia, while disease-associated variants could produce altered PSEN1 proteins.
Question
Do true gene-level loss-of-function variants in PSEN1 cause early-onset Alzheimer’s disease, or does disease require production of an altered PSEN1 protein? The study also re-examines the reported K109* variant in an affected father and son.
Method
The authors searched ADSP, UK Biobank, and BioVU for high-confidence PSEN1 variants, identifying 45 carriers of frameshift or stop-gain variants predicted to trigger nonsense-mediated decay; they assessed dementia diagnoses and age at last observation. They also examined 13 carriers of variants potentially producing truncated or alternatively spliced protein and used AlphaGenome, SpliceAI, and Pangolin to predict splicing effects of K109*.
Findings
-
Result
None of the 45 carriers of predicted PSEN1 null variants had recorded early-onset dementia; 42 had no recorded dementia, including 17 followed beyond age 65.
See the passage in the paper
Of the 45 individuals carrying high-confidence PSEN1 LoF mutations, none had early-onset dementia. 42 individuals remained dementia-free through their last assessment, including 17 carriers who were observed past age 65 (Figure 1).
-
Result
Six of the 13 carriers of potentially protein-producing splice or truncation variants had early-onset MCI or Alzheimer’s disease, and all six carried known exon 9 acceptor splice variants.
See the passage in the paper
Of these individuals, 6 had early-onset mild cognitive impairment (MCI) or EOAD, with disease onset before age 65. All early-onset cases were splice variant carriers at the exon 9 acceptor site (14:73206385:G:A and 14:73206385:G:T).
-
Result
Three splice-prediction models indicated that K109* could create a cryptic donor, producing an in-frame deletion rather than only a null allele.
See the passage in the paper
Three sequence-based splicing predictors all supported increased use of this cryptic donor and decreased use of the canonical exon 4 donor for the alternate allele (Figure 3C).
-
Authors’ interpretation
The authors infer that familial Alzheimer’s disease associated with PSEN1 requires an altered PSEN1 protein and that one normal allele appears sufficient for relevant PSEN1 functions.
See the passage in the paper
PSEN1-mediated FAD seems to require production of an altered PSEN1 protein product.
Limitations
- Dementia diagnoses and observation periods came from clinical records and cohort assessments, so undetected or later-onset diagnoses may not be captured.
See the passage in the paper
We also identified fewer than 20 carriers of PSEN1 LoF mutations in the AoU database; while specific findings could not be disclosed under AoU data dissemination policies, the observed phenotypes were consistent with our conclusions.
- The proposed cryptic splicing effect of K109* is computationally predicted in this study, rather than directly established by the reported cohort analysis.
See the passage in the paper
Three sequence-based splicing predictors all supported increased use of this cryptic donor and decreased use of the canonical exon 4 donor for the alternate allele (Figure 3C).
- The paper is a preprint that has not been peer reviewed.
See the passage in the paper
This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Why it matters
The authors argue that the findings distinguish gene-level PSEN1 loss of function from disease-causing variants that produce altered proteins, and provide a rationale for selectively suppressing mutant PSEN1 while preserving expression from the wild-type allele.
Written by AI from the paper. Passages are checked word for word against the text we analysed; the rest may contain errors.
Ask questions about this paper to our AI assistant
How to chat with this paper? Illustrated guide
You can also chat with multiple papers at once here.
Keep this conversation — a free account saves your questions and answers, your collections of papers and your alerts.
Continue with Google Create a free accountTools for this paper
Advanced tools Premium
For researchers who follow a field closely: citation alerts, journal-club slides, version comparison and Zotero export. Discover Premium
Papers around this one
See them on a mapRanked by how close their title and abstract are to this paper’s. Select some to read them together.
Closest papers
-
Presenilin 1 Mutations Converge on Aβ42/Aβ40 Elevation via Distinct MechanismsIsabel Bestard-Lorigados, Keenan Sterling, Li-Wei Li et al. · 2026 · MedComm · cited 1 time · Not summarized yet
Presenilin 1 Mutations Converge on Aβ42/Aβ40 Elevation tests how PSEN1 mutations alter protein processing, while this study asks whether PSEN1 loss-of-function variants cause EOAD.
Abstract
Mutations in Presenilin 1 (PS1) are the most common genetic cause of familial Alzheimer's disease (AD). However, the exact mechanisms by which these mutations alter amyloid precursor protein (APP) processing and drive amyloid β (Aβ) production remain unclear. In this study, five PS1 mutations (M146V, G384A, C410Y, Y115H, and the Notch‐sparing mutation ΔS169) were transfected into neuroblastoma cells lacking endogenous PS1/PS2 expression and human embryonic kidney cells stably overexpressing either wild‐type APP or the APP Swedish mutation. We investigated the effects of these mutations on APP processing, Aβ42/Aβ40 ratio, cytotoxicity, BACE1 expression, and PS1 endoproteolysis. Our results de…
-
Motor manifestations in PSEN1-Related early-onset Alzheimer’s disease: a case series and systematic reviewM. Genz, Ingrid Lorena da Silva Gomes, F. Junqueira et al. · 2026 · ANPAbstract_CBN26 · Not summarized yet
Motor manifestations in PSEN1-Related early-onset Alzheimer’s disease reviews clinical features among PSEN1-related EOAD cases, whereas this study tests whether PSEN1 null variants cause EOAD.
Abstract
Background: Autosomal dominant early-onset Alzheimer’s disease (EOAD) is a distinct subset of dementia, often affecting individuals during their working age. It is most frequently caused by pathogenic variants in PSEN1, accounting for the majority of genetically confirmed cases worldwide. Although typically characterized by amnestic cognitive decline, increasing evidence highlights substantial phenotypic variability among PSEN1 carriers, suggesting manifestations extend beyond the cognitive domain. Motor features, including pyramidal signs, dystonia and parkinsonism, have been reported in different stages of the disease, but are not routinely integrated into the recognized clinical spectrum.…
-
Effect of high-risk SORL1 variants on clinical presentation in symptomatic Alzheimer’s diseaseM. D. de Waal, Janna I. R. Dijkstra, L. Vermunt et al. · 2026 · Alzheimer's Research & Therapy · Not summarized yet
Effect of high-risk SORL1 variants on clinical presentation examines clinical outcomes in symptomatic AD carriers of another risk gene, rather than PSEN1 loss-of-function and EOAD.
Abstract
Rare, high-risk variants in SORL1 are established genetic contributors to Alzheimer’s disease (AD), but their impact on clinical presentation remains uncharacterized. This study investigates the effect of rare high-risk SORL1 variant ( SORL1 hi ) carriers on the clinical presentation, cognitive decline and time from diagnosis to death in symptomatic AD. Patients with a biomarker-confirmed diagnosis of symptomatic AD and available genetic information ( n = 1546, age at diagnosis 64.3 ± 7, 52% female, 69% APOE ε4 carriers) were included from the Amsterdam Dementia Cohort. SORL1 hi carriers were identified per established criteria, and wild-type (WT) carriers ( n = 1511) served as controls. Bas…
-
Tau A152T risk variant drives distinct cell type transcriptional signatures in AD and PSPMeredith T. Lilley, Ying-Xue Ren, Disha M. Soni et al. · 2026 · Acta Neuropathologica · Not summarized yet
Tau A152T risk variant drives distinct cell type transcriptional signatures studies another AD-associated genetic variant and its brain effects, not PSEN1 loss-of-function.
Abstract
The A152T point mutation is a rare genetic variant in the tau gene (MAPT) that is linked to risk of Alzheimer’s disease (AD) and frontotemporal dementia spectrum disorders, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). To uncover mechanisms through which the A152T variant contributes to risk of tauopathy, we performed single-nucleus RNA sequencing (snRNA-seq) on postmortem brain tissue collected from A152T carriers and pathology-matched non-carriers with either AD or PSP, along with age-matched controls. These efforts revealed that despite similar cell type composition across groups, A152T carriers exhibited distinct cell type-specific transcriptional ch…
-
Pregnancy History and Loss of Normal PSEN2 Function Impact Female Late-Life Cognitive Processing, Inhibitory Signaling, and GliosisJen-Nie I. Fang, Leanne Lehmann, K. Prater et al. · 2026 · bioRxiv · preprint, not peer reviewed · Not summarized yet
Pregnancy History and Loss of Normal PSEN2 Function examines PSEN2 function and cognition in female mice, while this study evaluates PSEN1 loss-of-function and EOAD.
-
Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s diseaseC. Ganoza, A. Westenberger, J. J. Paul et al. · 2026 · npj Parkinson's Disease · Not summarized yet
Data from the ROPAD study corroborate an association between ITSN1 loss-of-function variants and Parkinson’s disease uses genetic-database analyses to assess disease association of loss-of-function variants in another gene.
Abstract
We read with interest the recent studies by Skuladottir and colleagues and Coganandcolleagues,whichreportanovelassociationbetweenmonoallelic loss-of-function(LoF)variantsinthe ITSN1 gene and risk for Parkinson ’ s disease (PD) 1,2 . The fi rst study observed that heterozygous LoF variants in ITSN1 confer a large risk for developing PD in analyses combining the deCODE, UK Biobank, and Accelerating Medicines Partnership Parkinson ’ s Disease (AMP-PD) datasets 1 . The second study identi fi ed fi ve PD patients from three families who harbored distinct heterozygous frameshift ITSN1 variants and reported their clinical phenotype 2 . Yet another recent study reported similar results in an analysis o…
-
Genomic Landscape of Early-Onset and Familial Latin American Parkinson’s PatientsE. Waldo, H. M. Chaparro-Solano, M. Isayan et al. · 2026 · medRxiv · preprint, not peer reviewed · Not summarized yet
Genomic Landscape of Early-Onset and Familial Latin American Parkinson’s Patients screens disease-related genes for variants in early-onset and familial Parkinson’s disease.
Abstract
Background Parkinson's disease (PD), the most common neurodegenerative movement disorder, is commonly thought of as an aging and sporadic disease; however, 5-14% of individuals experience disease onset before the age of 50 years (early-onset PD; EOPD) and about 20% have a positive family history. In the case of both EOPD and people with a family history of PD, evidence suggests higher rates of a disease-causing genetic contribution. Objectives Our goal was to perform a variant screening of seven PD-related genes and 21 genes associated with related parkinsonian disorders to identify pathogenic/likely pathogenic variants and variants of uncertain significance within EOPD and family-history-po…
-
Alzheimer's disease genetics converges on microglial and neuronal dysregulation.E. Uffelmann, D. Wightman, S. Bahrami et al. · 2026 · Nature · Not summarized yet
Alzheimer's disease genetics converges on microglial and neuronal dysregulation analyzes genetic risk loci and biological pathways in AD, rather than PSEN1 null alleles specifically.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60-80%2. Although 1,200 causal loci are predicted to exist for AD3, approximately 80 loci have been associated with AD in two recent studies4,5. Low single-nucleotide polymorphism (SNP)-based heritability estimates have prompted the suggestion that little further common-variant risk remains to be found6. Here we analysed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional…
Go further
How are these papers found?
We compare the title and abstract of this paper with those of every paper summarized on this site, and with the papers Semantic Scholar recommends, those it cites and those citing it (for a much-cited paper, its most recent citations and, from OpenAlex, the most cited ones). Among the prior work and the follow-ups, the papers that use each other in depth, a method it uses and the much-cited follow-ups come a little higher. The levels (very close, close, related) come from the similarity of the texts, not from a judgment of quality; * marks a paper without an abstract, compared by its title. The sentence under a paper is written by an AI from the two abstracts: check it in the papers. A paper marked not relevant by three readers leaves the list.
Updated on 16 November 2026.
Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.